FibroGen, Inc.

FibroGen, Inc.

FibroGen, Inc.

Overview
Date Founded

1993

Headquarters

409 ILLINOIS STREET, SAN FRANCISCO, CA, 94158

Type of Company

Public

Employees (Worldwide)

599

Industries

Biotechnology
Pharmaceuticals

Company Description

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at FibroGen, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Executive Director, Clinical Development

Interim President

Chief Financial Officer & Chief Accounting Officer

Chief Commercial Officer

Chief Intellectual Property Officer

Chief Legal Officer

Chief Medical Officer

Chief Medical Officer

Senior Vice President-Drug Development

Board of Directors

Interim President at FibroGen, Inc.

Former President at Cardinal Health Systems, Inc.

Chairman at Cibus Corp.

Former President-Japan at Baxter International, Inc.

Chief Executive Officer at FibroGen, Inc.

Former Senior Vice President-Global Marketing & Commercial Development at Amgen, Inc.

President & Chief Executive Officer at Synlogic, Inc.

Co-Founder at Vividion Therapeutics, Inc.

Venture Partner Healthcare at Qiming Venture Partners Ltd.

Former Executive Vice President, Finance & Business Development & Chief Financial Officer at Allergan, Inc.

Paths to FibroGen, Inc.
Potential Connections via
Relationship Science
You
FibroGen, Inc.
Owners & Shareholders
Details Hidden

HCA seeks long-term, risk-adjusted returns through bottom-up analysis and fundamental proprietary research. As part of their bottom-up analysis, they perform both qualitative and quantitative assessments of potential investments with a particular focus on opportunities upon which it can gain insights and discover value in an ever-changing world. Their research process employs fundamental, quantitative, and qualitative analysis, including cyclical analysis. The firm generally focuses on publicly-listed (or similarly liquid) investment opportunities across multiple industries, but it may also participate in private (or otherwise less liquid) investment opportunities. HCA invests globally with a particular focus on companies or assets having substantial relations with Asia

Details Hidden

FCM seeks investments across asset classes and around the world through a process of bottom-up fundamental research and analysis emphasizing capital preservation. Their investment strategies include Credit Investments, Long/Short Equity, Merger Arbitrage, Risk Arbitrage, Real Estate Investments and Direct Investments. Investment ideas compete for capital based on in-depth, critical assessment of specific risks and rewards. Risk is monitored and managed through rigorous and thorough analysis of each investment and, at the portfolio level, through risk management analytics and overlay and tail-risk hedging.

Details Hidden

Vantage Consulting Group uses various methods of analysis in formulating investment advice and/or managing client assets. The firm may employ long-term and short-term purchases and trading in managing client accounts, provided that such strategy(ies) are appropriate to the needs of the client and consistent with the client's investment objectives, risk tolerance, and time horizons, among other considerations.

Recent Transactions
Details Hidden

FibroGen, Inc. issued USD Common Stock

Details Hidden

FibroGen, Inc. issued . USD Common Stock

Details Hidden

FibroGen, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onFibroGen, Inc. issued USD Common Stock

Auditor

Advised onFibroGen, Inc. issued USD Common Stock

Underwriter

Advised onFibroGen, Inc. issued USD Common Stock

Associate

Advised onFibroGen, Inc. issued USD Common Stock

Professional

Advised onFibroGen, Inc. issued USD Common Stock

Legal Advisor

Advised onFibroGen, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Founding Partner at Allen Matkins Leck Gamble Mallory & Natsis LLP

Advisor
Clients

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2020
Market Capitalization
$1.71B
Total Enterprise Value
$2.72B
Earnings Per Share
$-2.11
Revenue
$176M
Enterprise Value / Sales
15.45x
TEVNet Income
-14.39x
Debt TEV
0.02x
Total Debt
$58.5M
Total Equity
$441M
Net Profit
$-189M
EBITDAMargin
-96.32%
EBITDA
$-170M
Three Year Compounded Annual Growth Rate Of Revenue
11.95%
Investors
Details Hidden

T. Rowe Price Group, Inc. is a financial services holding company, which engages in the provision of investment management services through its subsidiaries. It provides an array of company sponsored U.S. mutual funds, other sponsored pooled investment vehicles, sub advisory services, separate account management, recordkeeping, and related services to individuals, advisors, institutions, financial intermediaries, and retirement plan sponsors. The company was founded by Thomas Rowe Price Jr. in 1937 and is headquartered in Baltimore, MD.

Details Hidden

VCFA seeks investments opportunities in the companies located in the US. The firm primarily focused on the acquisition of interests in private equity funds on a secondary basis .It provides liquidity to limited partners in venture capital, growth equity, buyout and other types of private equity funds. The firm focuses on the purchase of interests in promising companies backed by venture capital and growth equity funds. The firm seeks to provide consistent long-term private equity returns as well as co-investment opportunities when appropriate

Details Hidden

New Ventures invests in small and medium-sized, emerging market companies in the clean technology, biodiversity, renewable energy and sustainable forestry sectors. Investments range from $100,000 to $5 million. New Ventures screens businesses for financial outlook, innovation, market potential and social and environmental benefits. The firm invests in profitable companies that safeguard the environment and engage local communities while creating new markets and strong investment opportunities.

Suppliers
Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Dana-Farber Cancer Institute, Inc. Biotechnology | Boston, MA

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

University of Miami Schools & Student Services | Coral Gables, Florida

The University of Miami is a private research university in Coral Gables, Florida. As of 2019, the university enrolls 17,811 students in 12 separate colleges/schools, including the Leonard M. Miller School of Medicine in Miami's Health District, a law school on the main campus, and the Rosenstiel School of Marine and Atmospheric Science focused on the study of oceanography and atmospheric sciences on Virginia Key, with research facilities at the Richmond Facility in southern Miami-Dade County. The university offers 132 undergraduate, 148 master's, and 67 doctoral degree programs, of which 63 are research/scholarship and four professional areas of study. Over the years, the university's students have represented all 50 states and close to 150 foreign countries. With more than 16,000 full- and part-time faculty and staff, UM is a top 10 employer in Miami-Dade County. UM's main campus in Coral Gables has 239 acres and over 5.7 million square feet of buildings. Research is a component of each academic division, with UM attracting $358.9 million in sponsored research grants in FY 2019. UM offers a large library system with over 3.9 million volumes and exceptional holdings in Cuban heritage and music. UM also offers a wide range of student activities, including fraternities and sororities, a student newspaper and a radio station. UM's intercollegiate athletic teams, collectively known as the Miami Hurricanes, compete in Division I of the National Collegiate Athletic Association. UM's football team has won five national championships since 1983 and its baseball team has won four national championships since 1982.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

China Medical System Holdings Ltd. Pharmaceuticals - Shenzhen, China

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by FibroGen, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of FibroGen, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and FibroGen, Inc..